Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non-Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $43.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 15.23% to $43.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.5 million through Dec 2025, up 15.23% year-over-year, with the annual reading at $43.5 million for FY2025, 15.23% up from the prior year.
  • Other Non-Current Liabilities hit $43.5 million in Q4 2025 for Insight Molecular Diagnostics, down from $43.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $69.6 million in Q4 2021 to a low of $2.0 million in Q2 2024.
  • Historically, Other Non-Current Liabilities has averaged $27.4 million across 5 years, with a median of $32.1 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 94.98% in 2023 and later skyrocketed 2022.9% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $69.6 million in 2021, then crashed by 92.29% to $5.4 million in 2022, then crashed by 62.01% to $2.0 million in 2023, then surged by 1748.58% to $37.7 million in 2024, then grew by 15.23% to $43.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for IMDX at $43.5 million in Q4 2025, $43.9 million in Q3 2025, and $40.9 million in Q2 2025.